QUEST is a FREE newsletter published three times a year by the Urological Research Foundation. It informs readers of the latest advances in urologic research, especially prostate cancer treatment.
Please click here to subscribe to QUEST.
QUEST is a free newsletter, but we appreciate your support in helping the URF bring this publication to its readers.
Every year, the American Cancer Society releases new estimates on cancer cases and deaths in the U.S. The report in the journal CA: A Cancer Journal for Clinicians contained some excellent news: the cancer death rate has fallen continuously from…
The URF’s thoughts are with those affected by the coronavirus (COVID-19) pandemic. The Prostate Cancer Foundation has published special precautions for prostate cancer patients and their friends and loved ones during the coronavirus (COVID-19) pandemic. The coronavirus can affect the…
Recently, the American Urological Association (AUA) published its recommendations on incontinence after prostate cancer treatment, saying that the condition is “predictable and perhaps preventable.” First and foremost, the AUA statement recommends advising patients undergoing radical prostatectomy that incontinence is expected…
by Betsy Haberl Anthony F. Sansone, Sr. dedicated more than 25 years of service to the URF as President of the Board of Directors. He spoke to QUEST about his time with the URF and his long-standing friendship with Dr….
The Risk of Being Lost to Follow-Up on AS While active surveillance (AS) is becoming increasingly popular as a management strategy for patients diagnosed with low-risk prostate cancer, insufficient monitoring can put patients at risk for worse outcomes. A study…
The Urological Research Foundation supports Dr. Catalona’s trailblazing research in prostate cancer. This includes the SPORE Project he co-leads, which is the largest study to date of men on active surveillance. This research is doing important work identifying genetic variants…
In December 2019, the U.S. FDA expanded its approval of the drug enzalutamide to include treatment of men with metastatic castration-sensitive prostate cancer. Enzalutamide (brand name Xtandi) is an androgen receptor inhibitor that patients take orally. The drug is now…
A recent analysis calls into question the use of long-term hormone therapy for men with recurrent cancer and low PSA levels after prostate surgery. For men with recurrent prostate cancer after having radical prostatectomies, the latest standard of care usually…
Some studies have found correlations between men who eat a typical high-fat “Western” diet and worse prostate cancer outcomes. Conversely, some studies have found that men who eat a typical “Mediterranean” diet that is high in vegetables, fruits, and unsaturated…
Postoperative radiotherapy improves the chances for cancer-free survival in prostatectomy patients whose pathology report shows adverse findings. Examples of adverse findings are the extension of cancer cells through the capsule of the prostate, to the surgical margins of resection, or…